{
    "nct_id": "NCT04571138",
    "official_title": "Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-07: A Phase 1/2 Study of CD22-Specific CAR T Cells for CD22+ Leukemia or Lymphoma",
    "inclusion_criteria": "* Male and female subjects aged ≤ 30 years. First 2 enrolled subjects: age ≥ 18 and ≤ 30 years\n* Evidence of refractory or recurrent CD22+ leukemia or lymphoma\n* Able to tolerate apheresis, or subject with sufficient existing apheresis product or T cells for manufacturing investigational product.\n* Life expectancy ≥ 8 weeks\n* Lansky or Karnofsky, as applicable, score ≥ 50\n* Recovered from acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy, if the subject does not have a previously obtained apheresis product that is acceptable and available for manufacturing of CAR T cells\n* ≥ 7 days post last chemotherapy and biologic therapy, with the exception of intrathecal chemotherapy and maintenance chemotherapy\n* ≥ 7 days post last corticosteroid therapy\n* ≥ 3 days post Tyrosine Kinase Inhibitor (TKI) use\n* ≥ 1 day post hydroxyurea\n* 30 days post most recent CAR T cell infusion\n* Adequate organ function\n* Adequate laboratory values, including absolute lymphocyte count ≥ 100 cells/uL\n* Subjects of childbearing or child-fathering potential must agree to use highly effective contraception from consent through 12 months following infusion of investigational product on trial\n* Subject and/or legally authorized representative has signed the informed consent form for this study\nHealthy volunteers allowed\nMust have maximum age of 30 Years",
    "exclusion_criteria": "* Presence of active malignancy other than disease under study\n* History of symptomatic CNS pathology or ongoing symptomatic CNS pathology\n* CNS involvement of leukemia or lymphoma that is symptomatic and in the opinion of the investigator, cannot be controlled during the interval between enrollment and CAR T cell infusion\n* Subjects with uniform expression of CD19 on their malignant cells who are eligible but have not attempted CD19 directed CAR T cell therapy\n* For subjects having had a previous stem cell transplant: presence of active GVHD, or receiving immunosuppressive therapy for treatment or prevention of GVHD within 4 weeks prior to enrollment\n* Presence of active severe infection,\n* Presence of primary immunodeficiency syndrome\n* Subject has received prior virotherapy\n* Pregnant or breastfeeding\n* Subject and/or legally authorized representative unwilling to provide consent/assent for participation in the 15-year follow-up period, required if CAR T cell therapy is administered\n* Presence of any condition that, in the opinion of the investigator, would prohibit the subject from undergoing treatment under this protocol",
    "miscellaneous_criteria": ""
}